Trial Profile

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs F 0002 ADC (Primary)
Indications Anaplastic large cell lymphoma; Haematological malignancies; Hodgkin's disease; Myelofibrosis; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions
Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Most Recent Events

10 Dec 2024 Results of the phase I study assessing safety and preliminary efficacy of F0002 in patients with Relapsed or Refractory (R/R) classical Hodgkin Lymphoma (cHL) were presented at the 66th American Society of Hematology Annual Meeting and Exposition.
12 May 2024 Status changed from recruiting to completed.
13 Sep 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com